Blueprint Medicines (BPMC) to Release Quarterly Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) is expected to release its Q4 2024 earnings data before the market opens on Thursday, February 20th. Analysts expect Blueprint Medicines to post earnings of ($0.68) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. On average, analysts expect Blueprint Medicines to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Blueprint Medicines Stock Down 1.3 %

Blueprint Medicines stock traded down $1.25 during trading hours on Friday, hitting $93.94. 1,260,678 shares of the stock traded hands, compared to its average volume of 950,529. The firm's 50-day moving average price is $99.61 and its two-hundred day moving average price is $94.48. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The company has a market cap of $5.97 billion, a PE ratio of -44.52 and a beta of 0.62. Blueprint Medicines has a one year low of $77.57 and a one year high of $121.90.

Insider Buying and Selling

In related news, Director Jeffrey W. Albers sold 15,000 shares of the stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the completion of the transaction, the director now owns 157,557 shares of the company's stock, valued at approximately $14,143,891.89. This trade represents a 8.69 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kate Haviland sold 2,353 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80. Following the completion of the transaction, the chief executive officer now directly owns 150,824 shares of the company's stock, valued at approximately $14,569,598.40. The trade was a 1.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,851 shares of company stock valued at $4,984,696. Company insiders own 4.21% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on BPMC. Needham & Company LLC reaffirmed a "buy" rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research report on Thursday. Stephens reaffirmed an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Wedbush reaffirmed an "outperform" rating and issued a $128.00 price objective (up from $124.00) on shares of Blueprint Medicines in a research report on Thursday. JPMorgan Chase & Co. upped their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, JMP Securities reiterated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $123.83.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.